For the Inventor, By the Inventor

Enter assignee name

Ascentage Pharma (suzhou) Co., Ltd.

USPTO Granted Patents = 30

Trademarks = 17

Forward Citations = 8

Loading Chart...

Loading Chart...

57 inventors (with patents filed for the assignee):

Dajun Yang (17 out of 17 patents)

Yifan Zhai (17 out of 17 patents)

Douglas Dong Fang (12 out of 12 patents)

4. Qiuqiong Tang (7 out of 7 patents)

5. Jianfeng Wen (6 out of 6 patents)

6. Guangfeng Wang (6 out of 6 patents)

7. Ming Guo (5 out of 6 patents)

8. Tianzhu Wu (4 out of 4 patents)

9. Jianpeng Feng (4 out of 4 patents)

10. Huirong Lu (3 out of 3 patents)

11. Chao-Yie Yang (3 out of 15 patents)

12. Yunlong Zhou (3 out of 7 patents)

13. Yu Jing (3 out of 7 patents)

14. Shaomeng Wang (3 out of 77 patents)

15. Guozhi Tang (3 out of 4 patents)

30 patents: Sort by Forward Citations

1. 12370197 - Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2025-07-29),

2. 12358912 - Crystalline forms or amorphous forms of N-(phenyl sulfonyl) benzamide compounds or its salts or solvates (2025-07-15),

3. 12343352 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors (2025-07-01),

4. 12319703 - Macrocyclic fused pyrazoles as Mcl-1 inhibitors (2025-06-03),

5. 12287338 - Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway (2025-04-29),

6. 12268665 - Combination of immunotherapies with MDM2 inhibitors (2025-04-08),

7. 12233047 - Pharmaceutical combination and use thereof (2025-02-25),

8. 12221427 - Preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine or its salt, and intermediates thereof (2025-02-11),

9. 12194024 - Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease (2025-01-14),

10. 12186304 - Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule (2025-01-07),

11. 12152025 - Process for preparing alkynyl-containing compound and intermediate thereof (2024-11-26),

12. 12097195 - Pharmaceutical composition containing alkynyl compound and preparation method and application thereof (2024-09-24),

13. 12083136 - Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof (2024-09-10),

14. 11987575 - Tricyclic compounds as BCR-ABL inhibitors (2024-05-21),

15. 11872237 - Pharmaceutical composition and preparation method thereof (2024-01-16),

Ascentage Pharma (Suzhou) Co., Ltd. is a biopharmaceutical company dedicated to discovering and developing targeted small molecule drugs for the treatment of cancer and other challenging diseases. The company focuses on advancing its pipeline of novel therapies and has a strong track record of successful partnerships and collaborations with leading organizations in the industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

30 Patents

#17 in Suzhou

#916 in China

#21,168 in the World

Ascentage Pharma (suzhou) Co., Ltd.

Forward Citations = 8

57 inventors:

Dajun Yang (17 out of 17 patents)

Yifan Zhai (17 out of 17 patents)

Douglas Dong Fang (12 out of 12 patents)

4. Qiuqiong Tang (7 out of 7 patents)

5. Jianfeng Wen (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…